Sylvie Grégoire
Director/Board Member en NOVO NORDISK A/S .
Fortuna: 2 M $ al 31/03/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Prahlad Singh | M | 59 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 10 años |
John Alam | M | 62 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 21 años |
Helge Lund | M | 61 | 9 años | |
Alexis Michas | M | 66 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 23 años |
Lars Fruergaard Jorgensen | M | 58 | 33 años | |
Samuel Chapin | M | 66 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 8 años |
Michel Vounatsos | M | 62 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 4 años |
Joel Goldberg | M | 55 | 16 años | |
Tatjana Anni Hilde May | F | 58 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | 8 años |
Pascale Witz | F | 57 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 7 años |
Tajinder Vohra | M | 58 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 9 años |
Frank R. Witney Witney | M | 70 |
Revvity BV
Revvity BV Medical SpecialtiesHealth Technology PerkinElmer focuses on improving the health and safety of people and the environment. The company is headquartered in Zaventem, Belgium. | 8 años |
Madhav Devalaraja | M | 59 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 9 años |
Karsten Munk Knudsen | M | 53 | 25 años | |
Martin Hermanus Soeters | M | 70 | 18 años | |
John H. Rex | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Liselotte Hyveled | F | 58 | 29 años | |
Jeffrey Poulton | M | 56 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 1 años |
Marwan Noel Sabbagh | M | 58 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 3 años |
William Elder | M | 41 | 1 años | |
Yi Ping Lin | F | - | 1 años | |
Christina Law | F | 57 | 2 años | |
Francesco Maria Lavino | M | 51 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 3 años |
Maxwell Krakowiak | M | 35 | 6 años | |
Marcus Schindler | M | 57 | 6 años | |
Michelle McMurry-Heath | M | 54 | 2 años | |
Henrik Ehlers Wulff | M | 54 | 25 años | |
Bryan A. Kipp | M | - | - | |
Saiyed Mahmood | M | 48 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Susan Alexander | F | 67 | 21 años | |
Andreas Fibig | M | 62 | 6 años | |
William Tanner | M | 66 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 1 años |
Martin MacKay | M | 68 | 6 años | |
Peter Barrett | M | 71 | 12 años | |
Patrick Volkert Vink | M | 61 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 8 años |
Frank Zavrl | M | 58 |
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | 1 años |
Laurence Debroux | F | 54 | 5 años | |
Robert Cobuzzi | M | 60 | 1 años | |
Anita Gonzales | F | 48 | 1 años | |
Graham Hetherington | M | 65 |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
Sergey Manelis | M | - | 4 años | |
Will West | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Magali Four | F | - | 1 años | |
Michael Klobuchar | M | 48 | - | |
John Trainer | M | 50 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Miriame Victor | F | 43 | 1 años | |
Elisabeth Christensen | F | 59 | 2 años | |
Karsten Meisloch | M | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
Jayashree Kailas Thacker | F | - | 1 años | |
Ludovic Helfgott | M | 50 | 5 años | |
Heidrun Irschik-Hadjieff | F | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
Anderson Timothy | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Naveed Iqbal Siddiqi | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Uwe Fröhlich | M | 53 |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
Steve Willoughby | M | - | 3 años | |
Klaus Stöckemann | M | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
Mike Birch | M | - |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Simona Heidempergher | F | 56 |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Tom Gadek | M | - |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | - |
Sophie Vandebroek | M | 62 | - | |
Paul Eisenberg | M | - |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Madhuri Hegde | M | - | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Robert Friel | M | 68 | 20 años | |
Michael Davidson | M | 67 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 años |
Robert J. de Vaere | M | 66 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 4 años |
Timothy Walbert | M | 57 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 2 años |
Göran Albert Ando | M | 75 | 13 años | |
Ram Aiyar | M | - |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 5 años |
Rahul Kakkar | M | 49 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 4 años |
Jacques Turgeon | M | - |
Université Laval
| 9 años |
Michael Tomsicek | M | 58 | 5 años | |
Andrew Okun | M | 54 | 22 años | |
Jakob Riis | M | 58 | 21 años | |
Alphonse Galdes | M | 71 | - | |
James Tobin | M | 79 | 5 años | |
Kåre Schultz | M | 62 | 26 años | |
Claude Turcot | M | - |
Université Laval
| 7 años |
Lonnie Moulder | M | 66 | 5 años | |
Ben Harshbarger | M | 55 | 10 años | |
Brian Piekos | M | 49 | 5 años | |
Michael Kelly | M | 67 | 2 años | |
Christopher Guiffre | M | 56 | 7 años | |
Jessica Moreno | F | - | - | |
Timothy D. Hunt | M | - | 9 años | |
Lars Rebien Sørensen | M | 69 | 35 años | |
Kenton Sicchitano | M | 79 | 16 años | |
Marc M. P. de Garidel | M | 66 |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 2 años |
Mads Krogsgaard Thomsen | M | 63 | 30 años | |
Mario Lemay | M | - |
Université Laval
| 6 años |
Paul Clancy | M | 62 | 16 años | |
Tamara Joseph | F | 61 | 4 años | |
Gaétan Duplain | M | - |
Université Laval
| 5 años |
Nancy Hutson | M | 74 | 7 años | |
Mark Corrigan | M | 66 | 7 años | |
Hannu Ragnvald Ryöppönen | M | 72 | 6 años | |
Bruno Francois Jules Angelici | M | 77 | 6 años | |
Mary Szela | F | 61 | 3 años | |
André Boulet | M | - |
Université Laval
| 7 años |
Jesper Brandgaard | M | 60 | 20 años | |
Thomas Paul Koestler | M | 71 | 5 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 57 | 57.00% |
Dinamarca | 23 | 23.00% |
Reino Unido | 10 | 10.00% |
Bélgica | 7 | 7.00% |
Alemania | 7 | 7.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Sylvie Grégoire
- Red Personal